Tests a new tool to guide liver transplant choice in liver cancer
Tests a tool that picks liver cancer patients for transplant beyond usual criteria.
Plain-language title generated from the registry record
Registry title: HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
Key facts
- Where
- Lisbon, PortugalSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT04499833, who can take part
Where in Portugal
- Centro Hepato-bilio-pancreático e de Transplantação do Hospital Curry CabralLisbon, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centro Hospitalar de Lisboa Central
- Trial code
- NCT04499833
- Record updated
- 6 June 2022
- Original description
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphological models used in most centres (Milan Criteria), can exclude potential candidates and include patients with aggressive biological behaviour. To more accurately select candidates for liver transplant, the inclusion of criteria that could predict the behaviour and aggressiveness of tumours, such as molecular markers, might be useful.Read full original descriptionShow less
Evaluation of the HepatoPredict Prognostic Tool in the Decision of Liver Transplant in Hepatocellular Carcinoma
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphological models used in most centres (Milan Criteria), can exclude potential candidates and include patients with aggressive biological behaviour. To more accurately select candidates for liver transplant, the inclusion of criteria that could predict the behaviour and aggressiveness of tumours, such as molecular markers, might be useful.
The investigators propose the use of a new algorithm (HepatoPredict Prognostic Tool), that combine clinical and molecular criteria that address the biology of tumours, in a single centre prospective, intervention study. Data from the "HepatoPredict genomic signature" are added to the clinical and imagiology algorithm. Based on this tool, patients outside the usual eligibility criteria for liver transplant will be proposed for this treatment. These patients will be transplanted with marginal livers or with livers from patients with Familial Amyloid Polyneuropathy, not competing with patients on the waiting list. Patients will be followed up to 60 months after transplant, to assess survival and HCC recurrence with biannual imagiology screening. Survival and disease-free-survival rates will be compared with those obtained by the usual management of patients included and excluded by Milan Criteria.
Inclusion: Hepatocellular carcinoma associated with cirrhosis; Ages between 18 and 70 years; Total tumour volume below 500 cm3; Total number of tumour lesions below 10; Maximum individual tumour diameter below 10 cm.
Exclusion: eligible under the "Milan Criteria".